Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.71

+0.4%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: DewDiligence_on_SI	10/18/2005 10:19:22 PM
	Read Replies (1) of 52153

Update on the Cabilly patent: yahoo.reuters.com >> U.S. appeals court nixes Genentech patent lawsuit Tue Oct 18, 2005 05:59 PM ET WASHINGTON, Oct 18 (Reuters) - A federal appeals court on Tuesday reaffirmed a lower court's decision to throw out a MedImmune Inc. ( MEDI ) lawsuit challenging the validity of a key Genentech Inc. ( DNA ) patent. The U.S. Court of Appeals for the Federal Circuit agreed with a lower court's conclusion that legal doctrine prevents MedImmune from challenging a patent in court at the same time it licenses the same patent. The appeals court also rejected an argument by MedImmune that Genentech had colluded with rival Celltech when the two companies settled a dispute over the same patent -- known as the Cabilly patent -- in 2001. The Cabilly patent covers the method of producing antibody drugs, including Genentech's cancer treatments Avastin and Rituxan. <and many others such as Erbitux>. Loss of the patent could mean Genentech would lose as much as $300 million in annual royalty revenue, or 5 percent to 6 percent of its earnings, said Geoff Porges, an analyst at Sanford Bernstein. Genentech has licensed the patent, named after researcher Shmuel Cabilly, to MedImmune and other companies from which it collects royalties on the sales of their drugs. In September, in a separate action, the U.S. Patent Office rejected the Cabilly patent. But Genentech has said that ruling was a routine administrative move. And analysts have noted that final resolution of the matter could take years. <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next